FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3198347420> ?p ?o ?g. }

• W3198347420 endingPage "S310" @default.
• W3198347420 startingPage "S310" @default.
• W3198347420 abstract "Introduction: Hyperbaric oxygen therapy (HBO) is approved for difficult-to-treat tissue injury. It also been used as a second-line treatment for refractory infection in hematologic malignancies. However, data on the efficacy of HBO in such population are limited. Here, we reviewed our single-center experience of HBO used in patients with hematologic malignancies. Methods: We identified patients undergoing HBO treatment by insurance authorization data between December 2012 and October 2019 at MD Anderson Cancer Center. Patients with a diagnosis of hematologic malignancies with or without history of stem-cell transplant were included. Clinical and demographic data were collected by retrospective chart review. Results: A total of 50 patients were included: 26 (52%) patients had Acute Myeloid Leukemia, 31 (62%) patients had received an SCT, and 34 (68%) patients had active disease, of whom 28 (56%) had relapsed/refractory disease. The most common infections were: 19 (38%) BK cystitis and 17 (34%) fungal sinusitis. Median number of HBO sessions was 5 (range 1–60), and median HBO duration was 17 days (range 0–109). All patients received initial HBO in the hospital; 25 (50%) patients were discharged from hospital at either completion of HBO or after transition to outpatient treatment. Sixteen (32%) patients were discharged to hospice, and 8 (16%) patients died during the hospitalization. Ninety-day and 1-year mortality were high at 52% and 78%, respectively. Median survival was 3.1 months. Patients with BK cystitis were less likely to respond to HBO (odds ratio 0.16, p=.004). Eight patients had response to HBO and achieved remission of infection at last follow-up. These patients had a higher proportion (50%) of underlying disease in remission, compared to 29% in rest of patients (n=42). The treatment indications in the responding group were 2 BK cystitis, 2 fungal sinusitis, 2 cellulitis, and 2 non-BK cystitis. Other patient characteristics were similar to the rest of the patients. Patients with response/infection remission had better survival with HR 0.18 (95% CI .063–.529, p=.002). Conclusion: A small subset of patients with hematologic malignancies, 16% in our study, had meaningful recovery from infection after HBO treatment. In our experience, patients whose underlying malignancy was in remission and patients with non-BK infection had better outcomes. Additional studies are needed to better identify the population who would benefit from HBO." @default.
• W3198347420 created "2021-09-13" @default.
• W3198347420 creator A5028845635 @default.
• W3198347420 creator A5030138645 @default.
• W3198347420 creator A5030631684 @default.
• W3198347420 creator A5086011253 @default.
• W3198347420 creator A5087990089 @default.
• W3198347420 date "2021-09-01" @default.
• W3198347420 modified "2023-09-26" @default.
• W3198347420 title "AML-410: Efficacy of Hyperbaric Oxygen Therapy in Hematologic Malignancy Patients: A Single Comprehensive Cancer Center Retrospective Review of 50 Patients" @default.
• W3198347420 doi "https://doi.org/10.1016/s2152-2650(21)01734-1" @default.
• W3198347420 hasPublicationYear "2021" @default.
• W3198347420 type Work @default.
• W3198347420 sameAs 3198347420 @default.
• W3198347420 citedByCount "0" @default.
• W3198347420 crossrefType "journal-article" @default.
• W3198347420 hasAuthorship W3198347420A5028845635 @default.
• W3198347420 hasAuthorship W3198347420A5030138645 @default.
• W3198347420 hasAuthorship W3198347420A5030631684 @default.
• W3198347420 hasAuthorship W3198347420A5086011253 @default.
• W3198347420 hasAuthorship W3198347420A5087990089 @default.
• W3198347420 hasConcept C121608353 @default.
• W3198347420 hasConcept C126322002 @default.
• W3198347420 hasConcept C141071460 @default.
• W3198347420 hasConcept C167135981 @default.
• W3198347420 hasConcept C2780073493 @default.
• W3198347420 hasConcept C2908647359 @default.
• W3198347420 hasConcept C71924100 @default.
• W3198347420 hasConcept C99454951 @default.
• W3198347420 hasConceptScore W3198347420C121608353 @default.
• W3198347420 hasConceptScore W3198347420C126322002 @default.
• W3198347420 hasConceptScore W3198347420C141071460 @default.
• W3198347420 hasConceptScore W3198347420C167135981 @default.
• W3198347420 hasConceptScore W3198347420C2780073493 @default.
• W3198347420 hasConceptScore W3198347420C2908647359 @default.
• W3198347420 hasConceptScore W3198347420C71924100 @default.
• W3198347420 hasConceptScore W3198347420C99454951 @default.
• W3198347420 hasLocation W31983474201 @default.
• W3198347420 hasOpenAccess W3198347420 @default.
• W3198347420 hasPrimaryLocation W31983474201 @default.
• W3198347420 hasRelatedWork W1158067 @default.
• W3198347420 hasRelatedWork W13242404 @default.
• W3198347420 hasRelatedWork W16019997 @default.
• W3198347420 hasRelatedWork W16128638 @default.
• W3198347420 hasRelatedWork W18431496 @default.
• W3198347420 hasRelatedWork W1849033 @default.
• W3198347420 hasRelatedWork W19987220 @default.
• W3198347420 hasRelatedWork W373436 @default.
• W3198347420 hasRelatedWork W8076426 @default.
• W3198347420 hasRelatedWork W8705116 @default.
• W3198347420 hasVolume "21" @default.
• W3198347420 isParatext "false" @default.
• W3198347420 isRetracted "false" @default.
• W3198347420 magId "3198347420" @default.
• W3198347420 workType "article" @default.